- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Here's a concise summary of Balaji Amines' Q1 FY27 investor presentation:
**1. Business Performance:**
Balaji Amines commenced FY27 on a strong note, delivering healthy operational and financial performance with resilient margins. Its core chemical business continues to deliver a superior Return on Capital Employed (RoCE), reflecting strong fundamentals and manufacturing capabilities.
**2. Growth Drivers or Strategy:**
The company is strategically transitioning into a high-value speciality chemicals platform, driven by significant import substitution opportunities and products linked to the EV battery sector. Key strategic focus includes disciplined expansion of its differentiated speciality chemicals portfolio.
**3. Recent Developments:**
Q1 FY27 saw the successful commissioning of India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant. Additionally, N-Methyl Morpholine (NMM) and Acetonitrile (ACN) expansion projects, along with Balaji Speciality Chemicals Limited (BSCL) expansions for HCN, Sodium Cyanide, EDTA, and EDA derivatives, are all progressing on track for commissioning by the end of FY27.
**4. Key Financial Metrics:**
Consolidated revenue for the quarter grew 25.73% year-on-year to 461 Cr. Profit After Tax (PAT) surged 110.19% year-on-year to 78 Cr, while consolidated EBITDA reached 121 Cr, up 91.51% YoY. Earnings Per Share (EPS) for Q1 FY27 stood at 23.13.
**5. Management Commentary / Outlook:**
Management expressed confidence in delivering sustainable growth, projecting FY27 volume growth of 10-15% and medium-term growth of 20-30%. Earnings acceleration is anticipated as newly commissioned DME, NMM, ACN, and BSCL projects ramp up, with an EBITDA margin targeted at 22-23% for FY27.